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Summary: The urine and plasma of epileptic patients receiving therapeutic doses of valproic acid (2-propyl-
pentanoic acid) was found to contain five doubly unsaturated metabolites of valproic acid, which were identi-
fied äs their trimethylsilyl derivatives by GC/MS. A series of reference substances was synthesized but only
two of them were identical with native metabolites: 2(2-propenyl)-4-pentenoic acid (= 4.4'-diene) and E-2-
propyl-2.4-pentadienoic acid (E-2.4-diene). The mass-spectra of the five native metabolites are given. Preli-
minary quantitative data obtained from four groups of patients indicate increased formation of doubly unsatu-
rated metabolites when valproic acid-induced side-effects are present, and in cases of fatal hepatic failure. The
4.4'-diene has hitherto been found only in fatal cases with hepatic injury. Quantitative data are presented äs
% of the sum of valproic acid plus all its detected metabolites.
Fünf zweifach ungesättigte Metabolite der Valproinsäure in Urin und Plasma von epileptischen Patienten unter
Behandlung mit Valproinsäure
Zusammenfassung: In Urin und Plasma von epileptischen Patienten unter Behandlung mit Valproinsäure (2-
Propylpentansäure) konnten insgesamt fünf zweifach ungesättigte Metabolite der Valproinsäure als Trime-
thylsilyl-Derivate durch GC/MS identifiziert werden. Eine Reihe von Referenzsubstanzen wurde syntheti-
siert, aber nur zwei Von ihnen waren mit nativen Metaboliten identisch: 2(2-PropenyI)-4-pentensäure
(= 4.4'-dien) und E-2-Propyl-2.4-pentadiensäure (= E-2.4-dien). Die Massenspektren der fünf nativen Me-
tabolite werden angegeben. Vorläufige quantitative Ergebnisse aus vier Gruppen von Patienten zeigen eine
erhöhte Bildung von zweifach ungesättigten Metaboliten bei Valproinsäure-induzierten Nebenwirkungen und
bei letalen Leberschäden. Das 4.4'-Dien konnte bisher nur bei Todesfällen mit Leberintoxikation nachge-
wiesen werden. Die quantitativen Werte werden in % der Summe aus Valproinsäure und allen nachgewiese-
nen Metaboliten angegeben.
Introduction
Valproic acid (2-propyl-pentaiioic acid) is a widely
used antiepileptic einig extremely effective against
absence and generalized toiuc-clonic seizures {!). It
was commonly believed to be relatively free from
adverse side-effects. During recent years, however,
*) Supported by Deutsche Forschungsgemeinschaft
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it has been incriminated äs the cause of severe, and
in some instances fatal hepatic injuries (2). Through-
out the world, a total of 68 fatal cases have been
recognized (3). Early calculations revealed frequen-
cies of 1:10000-1:20000 (4) and 1:50000 (5). The
pathogenesis of this fatal hepatic failure is not under-
stood and the first case in which valproic acid metab-
olism could be studied was published by Kochen et
al. (6). The prominent feature in this patient was the
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abnormally increased formation of mono- and di-un-
saturated metabolites of vaiproic acid. Therefore it
seems necessary to further investigate this new group
of doubly unsaturated metabolites, which we report-
ed earlier (7).
There are substantial problems in the synthesis of
doubly unsaturated derivatives of vaiproic acid, be-
cause the introduction of two double bonds results in
14 different stereoisomers. Moreover, if carbon 2 in
vaiproic acid becomes chiral then an additional 4
enantiomers must be taken into consideration: Both
stereoisomers of the 3.4'-diene form enantiomers
(D- and L-2(2-propenyl)-3-rmw-pentenoic acid
and £>- and L-2(2-propenyl)-3-cw-pentenoic acid).
In the case of the 3.3'-diene only 2(l-ira/2,s-propen-
yl)-3-c/s-pentenoic acid may be expected to form
enantiomers.
In the present work, we report the detection of a to-
tal of five doubly unsaturated metabolites of vaiproic
acid in patients ori vaiproic acid therapy. Preliminary
quantitative data indicating the possible pathological




The syntheses of doubly unsaturated vaiproic acid derivatives
have been described by Klemens (8).
All these compounds have not been described in literature except
the 4.4'-diene (9, 10).
2(2-Propenyl)-4-pentenoic acid (4.4'-diene) was obtained by ma-
lonic ester synthesis using allylbromide, followed by saponifica-
tion and decarboxylation.
2(2-Propenyl)-3-pentenoic acid (3.4'-diene): Knoevenagel-reac-
tion of propionaldehyde and diethylmalonate, alkylation of the
propylidenediethylmalonate with l-bromopropene-2, saponifica-
tion and decarboxylation.
2(2-Propenyl)-2-pentenoic acid (2.4'-diene): acylation of diethyl-
malonate with propionylchloride, alkylation with allylbromide,
reduction by NaBH4, decarboxylation, dehydration and saponifi-
cation.
2-Propyl-2.4-pentadienoic acid (2.4-diene) was obtained by a
Wittig reaction with 2-bromoethylpentanoate and acrolein.
2(l-Propenyl)-2-pentenoic acid (2.3'-diene): nucleophilic acyla-
tion of 1-bromopropane with umgepoltem crotonaldehyde fol-
lowed by saponification.
Mass-spectra of the synthetic diene compounds
The synthetic products were purified by common methods. The
trimethylsilylesters of the acids were analysed by GC/MS.
Determina t ion of vaiproic acid metabolites by GC/MS
Sample preparation
50-200 μΐ of the sample (urine, plasma etc.) wefe added to 200 μ!
of 0.5 mol/1 NaH2PO4 buffer pH 5.0 containing 3 internal Stan-
dards (l μ§ each of di-n-butylacetic acid, phenylbutyric acid and
Ci9-alkane) and 20 μΐ glucuronidase/arylsulphatase (Serva, Hei-
delberg). After incubation of the mixture for 3 h at 37 °C the me-
tabolites were extracted with ethyl acetate (3 times; 0.5 ml). The
volume of the combined organic phases was reduced to about
20 μΐ (not to dryness!) under a stream of dry nitrogen. The acids
were silylated with 10 μΐ Ν^6
ide (MSTFA, Machery & Nagel, D ren).
Gas-Chromatographie conditions
50 m capillary glass column SE-54 (Jaegi, Trogen, Switzerland),
split 1:20, temperature programme 75 °C (10 min), 4 °C/min up
to 200 °C, Pj 1.2 bar (He). Mass-spectrometer DuPoiit 21-492 B,
open interface combination, ionisation energy 70 eV, ion source
temperature 250 °C, interface 210°C.
Quantification
Vaiproic acid, its metaboiites and the internal Standards were
rnass-fragmentographically determined by means of M+ — 15
mass-ions. Calibration samples were prepared s above. Quantifi-
cation of diene/3 and diene/4 was performed by using two other
synthetic diene derivatives with identical intensities of m/z 197
and 122 s in the native metabolites.
Results
Synthet ic diene compounds
GC/MS investigations demonstrated that the syri-
thesized products consisted of mixtures of isomers,
which we have numbered /l, /2, etc. according to
their increasing retention time. The isomers were not
isolated and the stereo-chemical str cture remains
unknown. Table l presents the mass-ions and their
intensity in % base-peak. The most intensive mass-
ion above m/z 100 was selected Ιοί the base-peak;
the fragments below m/z 90 were considered to be of
minor importance, and were therefore ignored. In
investigating new syntheses for diene compounds
without a terminal double bond, we obtained a series
of doubly unsaturated vaiproic acid derivatives
which were characterized by GC/MS. Three of these
(diene-S5, diene-S6, and diene-S7) are also listed in
tablel.
Native diene metabolites
Synthetic hydroxylated vaiproic acid derivatives (hy-
droxylated in position 5, 4, 3 and 2) were added to
control samples of urine and plasma, and the sam-
ples prepared for GC-analysis s described in ineth-
ods. Mass-fragmentographic analysis of hydroxylat-
ed vaiproic acid derivatives did not generate detecta-
ble unsaturated derivatives, i.e. dehydration does
not occur under the conditions used.
As an example figure l presents the mass-fragmen-
tographic chromatogram of a urine sample from an
epileptic and extremely dystrophib patient treated
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Tab. l. Synthetic diene compounds of valproic acid and the EI mass^spectra of their trimethylsilyl derivatives. The most intense mass-ion
above m/z 100 was taken äs base-peak (100%). Mass-ions below m/z 90 were abandoned. For further details of dienes S5, S6
and S7 see text.
Compound m/z (% base-peak)
2(2-Propenyl)-4-pentenoic acid
(4.4'-diene)
2(2-Propenyl)-3-pentenoic acid, Ist isomer
(3.4 '-diene/1)
2(2-Propenyl)-3-pentenoic acid, 2nd isomer
(3.4'-diene/2)
Diene-Sl l: additional diene ftom synthesis
of 3.4'-diene
2(2-Propenyl)-2-pentenoic acid. Ist isomer
(2.4'-diene/l)
2(2-Propenyl)-2-pentenoic acid, 2nd isomer
(2.4'-diene/2)
2-Propyl-2.4-pentadienoic acid, Ist isomer
(2.4-diene/l)
2-Propyl-2.4-pentadienoic acid, 2nd isomer
(2.4-diene/2)





197 (100), 94 (64), 117 (37), 171 (34), 111 (23), 169 (20), 122 (15), 105 (8)
197 (100), 155 (29), 81 (26), 171 (22), 94 (20), 169 (17), 170 (16), 117 (16), 212 (12),
156 (12), 111 (8), 122 (5), 157 (5)
171 (100), 197 (68), 117 (49), 156 (35), 95 (20), 125 (18), 129 (13), 111(11), 112(10),
212 (8), 155 (7), 143 (7), 122 (5), 118 (5)
197 (100), 212 (74), 122 (20), 96 (10), 123 (10), 183 (8), 167 (7), 156 (6), 107 (6),
110(5)
197 (100), 94 (50), 117 (34), 155 (30), 171 (28), 111 (22), 169 (17), 122 (16), 170 (14),
156(14), 129 (11), 212(11)
197 (100), 122 (73), 212 (70), 123 (39), 93 (22), 107 (17), 95 (17), 167 (17), 124 (11),
181(10), 183(9), 155(5), 125(5)
197 (100), 183 (97), 122 (79), 123 (35), 95 (23), 153 (9), 155 (8), 169 (7), 184 (7),
117(6),
122 (100), 197 (75), 123 (50), 183 (31), 212 (25), 196 (12), 107 (10), 181 (7), 167 (7),
155 (7), 111 (5), 169(4)
197 (100), 122 (45), 212 (40), 183 (40), 123 (30), 110 (13), 95 (12), 196 (10), 152 (10),
124(10), 167(8)
212 (100), 197 (96), 122 (88), 93 (22), 167 (18), 123 (15), 181 (14), 95 (13), 107 (10),
101 (8), 115 (6), 173 (6), 117 (5), 112 (4)
122 (100), 197 (89), 212 (85), 147 (42), 95 (35), 140 (21), 167 (14), 181 (9), 107 (8),
169 (8), 157 (7), 111 (6), 131 (6), 117 (4)
197 (100), 212 (40), 122 (31), 117 (15), 129 (14), 133 (11), 123 (9), 183 (6), 156 (6),
184 (5), 169 (5)
with valproic acid. The usual mono-ene metabolites
2-propyl-3-pentenoic acid (3-ene) and 2-propyl-2-
pentenoic acid (Z- and E-2-ene) (see arrow 2, 3 a
and 3b), the oxidized metabolites (see arrow 8—12),
and three doubly unsaturated metabolites E-2-prop-
yl-2.4.-pentadienoic acid (== E-2.4-diene, diene/l),
diene/2, and diene/3 (see arrow 4—6) are all clearly
demonstrated. Due to their low concentration it is
usually impossible to detect them on the basis of the
total ion current (TIC) alone, and especially diene/3
is ofteri hidden in the overlapping urea peak. Remo-
val of urea by urease before extractiön remarkably
facilitates the detection of diene/3. Mass-spectra of
the diene metabolites were obtained from urine sam-
ples containing elevated amounts of the compounds
concerned. The typical mass-fragmentographic iöns
of the trimethylsilyl derivatives are the molecular ion
m/z 212 and the M - 15 mass m/z 197.
The mass spectfum of diene/l trimethylisilyi deriva-
tive (arrow 4 in fig. 1) is given in figure 2a and agrees
well with that of the second isomer from the synthe-
sis of 2-propyl-2.4-pentadienoic acid trimethylsilyl
derivative (see fig. 2b). The retention time of the na-
tive product is identical with that of the synthetic iso-
mer characterized by the higher retention time
(compare fig. 8). The M — 15 mass ion of the native
product was determined at m/z 197.0945 (theoreti-
cal value 197.0998). In view of the higher retention
time of this isomer we assume that it has the follow-






The Irans position of the carboxylic and the ethylene
group may also be derived from the stereoselective
course of the synthesis (11).
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Fig. 1. GC/MS chromatogram of a hydrolysed urine sample of a patient treated with valproic acid (VPA). Mass-ions are given in the 3
channels, attenuation on the left side of each channel. TTypical mass-ions of the metabolites äs trirnethylsilyl derivatives are
indicated by arrows.
TIC = total ion current.
Valproic acid metabolites:
1) 2-propyl-4-pentenoic acid (4-ene),
2) 2-propyl-3-pentenoic acid (3-ene, sum of eis and trans),
3a and 3b) 2-propyl-2-pentenoic acid ((Z)2-ene and (E)2-ene),




8a and 8b) diastereomers of 2-propyl-4-hydroxy-pentanoic acid,
9) both diastereomers of 2-propyl-3-hydroxy-pentanoic acid,
lOa and lOb) 2-propyl-3-hydroxy-2-pentenoic acid (3-ketoenol),
11) 2-propyl-5-hydroxy-pentanoic acid,
12) 2-propyIglutaric acid,
13) urea and other constituents.









GC-conditions see text. · »
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Fig. 2. Mass-spectrum of
a) native E-2^propylr2.4-pentadienoic acid (diene/l,
trimethylsilyl derivative),
b) synthetic 2-propyl-2.4-pentadienoic acid trimethylsilyl
derivative (second isomer with higher retention time).
The mass-spectrum of diene/2 trimethylsilyl deriva-
tive (see arrow 5 in fig. 1) is given in figure 3 and is
likewise characterized by the base^peak of m/z 122
s in E-2-propyl-2.4-pentadienoic acid trimethylsilyl
derivative (= diene/l). Exactly defined reference
compounds are not available for either diene/2 or
the diene metabolites discussed in the following. As













Fig. 3. Mass-spectrnm of native diene/2 trimethylsilyl derivative.
pounds have shorter retention times. Only the syn-
thetic products, diene-S5, diene-S6, and diene-S7
were found in small amounts s by-products in the
synthesis of the 2.3'-diene and 3.3'-diene. Their
mass-spectrometric data indicating a diene structure
are therefore also listed in table 1. The positions of
the two double bonds in these three unsaturated pro-
ducts were not elucidated.
In spite of the identical retention time of diene/2 and
the synthetic product diene-S5 their mass-spectra
differ with respect to the relative intensities of the
typical mass-ions.
The mass-spectrum of diene/3 trimethylsilyl deriva-
tive (fig. 4) is also in accordance with the presence of
a doubly unsaturated metabolite s confirmed by
high-resolution of the molecular ion (found m/z
212.1195, theoretical value 212.1232).
The following two doubly unsaturated metabolites
were detected and identified in fatal cases (6, 12),
where s they are unknown in patients without com-
plications. Identification of 2(2-propenyl)-4-penten-
oic acid (4.4'-diene) was possible only because the
samples of the patient concerned (6) contained a
veiy low concentration of valproic acid. As demon-
strated in figure 5, the trimethylsilyl derivatives of
the synthetic 4.4'-diene> 4-ene and valproic acid are
eluted very close together under the gas Chromato-
graphie conditions used, so that in the presence of an
excess of valproic acid it is difficult to detect these
J. Clin. Chem, Clin. Biochem. / Vol. 22, 1984 / No. 4
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two metabolites. The mass-spectrum of the native
4.4'-diene trimethylsilyl derivative is given in figure
6 and agrees well with that of the synthetic product.
The relative intensity of m/z 122 amounts only to
about 15% and the molecular ion m/z 212 ist not
higher than 10% of the base-peak m/z 197, whose
exact mass was determined at 197.1092 (theoretical
value 197.0998).
The 4.4'-diene is not present in the sample shown in
figure l, but the 4-ene (arrow 1) is present in inore
than trace amounts. This metabolite is not normally
detectable in urine or plasma, and its existence was
confirmed by the characteristic mass-ions m/z 172
and 185 and by the addition of the authentic refer-
ence compound. The mass-spectrum of the 4-ene
has been published in I.e. (6).
The last of the five diene metabolites has the highest
retention time and is termed diene/4. As in the case
of diene/3, it may be overlapped by urea. The mo-
lecular ion was determined at m/z 212.1300. The
typical mass-ions indicate again a doubly unsaturat-
ed metabolite, although an authentic reference sub-
stance is still lacking (mass-spectrum fig. 7). In figure
l traces of diene/4 were also detected by recording
m/z 122. ' '
A comparison of the retention indices of both the
synthetic and the native diene compounds is given in
figure 8. The synthetic products, diene-S5, diene-S6
and diene-S7 are not defined in respect to the posi-
tion of the two double bonds and they are listed only
on the basis of their increasing retention times,
which are in the same order s those of the native
diene-metabolites, diene/2, diene/3, and diene/4.
For analytical purposes the ex ct relative retention
times of the trimethylsilyl derivatives of valproic
acid, the five diene metabolites, and the mono-ene
metabolites are summarized in table 2. The gas Chro-






























































































































































Fig. 5. GC/MS chromatogfam of synthetic valproic acid (VPA), 2-propyl-4-pentenoic acid (4-ene), arid 2(2-ptropenyl)-4-pentenoic
acid, (4.4'-diene) s trimethylsilyl derivatives.
GC-conditions s in figure 1. TIC = total ion current. *
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Fig. 7. Mass-spectrum of native diene/4 trimethylsilyl derivative.
other urinary acidic constituents which, depending
on their Concentration, may completely overlap
these valproic acid metabolites. The commonly
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Fig. 8. Retention indices of synthetic and native diene derivatives
of valproic acid (VPA) s trimethylsilyl derivatives. GC-
conditions s in figure 1.
Concentrat ion of the diene m e t a b o l i t e s in
pat ients on valproic acid the rapy
Preliminary quantitative results for diene metaboli-
tes found in four groups of patients (adults without
side-effects, children with reversible side-effects
such s vomiting, drowsiness, anorexia etc, one fatal
case with hepatic failure (6), and children without
complications in therapy) are given in table 3 in % of
the sum of valproic acid plus all detected and quanti-
fied metabolites (= 100%). These percentages have
proved to be more informative than the absolute
quantitative data of the single metabolites. Besides
Tab. 2. Trimethylsilyl derivatives of the mono-ene- and diene metabolites of valproic acid: retention times (Rt) are related to the
internal Standards, di-n-butylacetic acid trimethylsilyl derivative, phenylbutyric acid trimethylsilyl derivative, and Cjy-alkane.
The contamination products listed are usually observed together with the metabolites in the urinary samples under the GC-con-
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Tab."3. Concentration of diene metabolites of valprpic acid in patients on valproic acid therapy. Values are given in % of the sum
valproic acid plus all determined metabolites. For details see text.
Metabolite Adult patients (n = 5)
Plasma Urine
Reversible side-effects
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the diene metabolites, the following metabolites are
included: E-2-ene and Z-2-ene, cw-3-ene and trans-
3-ene, 4-ene, 2-propyl-3-hydroxypentanoic acid, 2-
propyl-3-oxopentanoic acid, 2-propyl-4-hydroxy-
pentanoic acid, 2-propyl-5-hydroxypentanoic acid
and 2-propylglutaric acid. It is evident that both the
number and the concentration of the single diene
metabolites are increased if clinical side-effects are
present. Drastically enhanced amounts were found
in a case with fatal hepatic failure (6). Similar results
were obtained in 4 other fatal cases, although the
concentrations of the diene metabolites in plasma
and urine were not so greatly elevated äs in the pa-
tient cited, and the metabolic patterns were slightly
different (12).
E-2.4-diene, diene/2, and diene/3 may be regarded
äs normal metabolic products, and the last one is al-
ways the most prominent doubly unsaturated metab-
olite. E-2-4-diene is sometimes missing, and when
present, its concentration is always very low in nor-
mal patients. In contrast, the 4.4'-diene is thought to
be abnormal due to its complete absence from child-
ren and adults treated without complications.
Diene/4 was sporadically observed only in adults,
and its enhanced formation in the presence of side-
effects and hepatotoxicity qualified this metabolite
äs possibly toxic.
Discussion
So far, we have detected a total of 5 doubly unsatu-
rated metabolites of valproic acid. There are numer-
ous possible isomers of these diene metabolites,
which cannot be reliably differentiated and charac-
terized by mass-spectrometry. To ensure the correct
assignment of the two double bond positions, we
therefore synthesized a series of doubly unsaturated
derivatives of valproic acid (8). Only two of these
synthetic compounds were found to be identical with
native metabolites: 2(2-propenyl)-4-pentenoic acid
(4.4;-diene) and E-2-propyl-2.4-pentadienoic acid
(E-2.4-diene). The three other native diene metabo-
lites are still non-defined with respect to the positioii
and stereochemistry of the two double bonds. They
are therefore termed diene/2, diene/3, and diene/4.
However, their exact structures may be inferred
from figure 8, and these are illustrated in the meta-
bolic scheine in figure 9. All possible diene deriva-
tives containing a terminal double bond have been
synthesized and the retention times of these com-
pounds are smaller than those of the native metabo-
lites, diene/2, diene/3 and diene/4.
Some of the synthetic products containing a terminal
double bond have the same retention time äs the me-
tabolic products, i.e. 4-ene, 4.4'-diene, and E-2.4-
diene. Furthermore, it may be concluded from figure
8, that
a) the two double bonds in the native diene/2,
diene/3, and diene/4 metabolites are distributed in
both cafbon chains, f
b) the possibility of a terminal double bond in these
three metabolites can be excluded, and
c) only 3.3'-diene isomers (3^trans/3'-cis, 3-oy/3'-
cis, 3-transl3'-trans) or 2.3'-diene isomers (2-transl
3'-trans, 2-cis/3'-cis, 2-cis/3'-trans, 2-trans/3'-cis)
may be predicted.
This means that one double bond must be localized
in 3, 4 position of the metabolites diene/2, diene/3
and diene/4. A shift of the terrninal double bond to
the inner tertiary carbon atom is accompanied by an
increäse in retention time (see fig. 8). Therefore, the
structure of diene/4 and also of diene/3 is assumed
to be rather a 2.3'-diene than a 3.3'-diene; Since the
2-ene is the main metabolite of the mono-ene group,
its function äs a precursor is more plausible than that
of the 3-ene, normally only of minor importance.
Consequently, diene/2 might be assigned a 3.3'-
diene structure with the 3^ene äs precursor.
The formation of the E-2.4-diene is unusual in so far
äs the second double bond is introduced into the
propenylic and not into the propylic group. In this
connection, it should be lioted that 2.4^pentadienoic
acid is formed metabolically from 4-pentenoic acid
(13).
The metabolic pattern of valproic acid metabolism in
fatal hepatic failure is characterized by an increased
formation of doubly unsaturated metabolites äs ex-
emplified in a patient (see tab. 3) (6). The 4.4'-diene
is considered to be an abnormal metabolite, which is
never found in patients without severe complica-
tions. Its formation seems to be always accompanied
by the 4-ene, which may also be sporadically ob^
served in normal patients (but not more than
0.05%). The toxic effects of the 4-ene are thought to
be analogous to the features of Reye's syndrome in-
duced in rats by 4-pentenoic acid (14). As the 2-ene
(main metabolite of the mono-ene group) and the 3·̂
ene äs well äs the E-2.4-diene, diene/2, and diene/3
(main metabolite of the diene group) are normal and
almost obligatory metabolites, the distinct appear-
ance of the 4.4'-diene, the 4-ene, and the diene/4 in
fatal hepatic damage (6, 12) may indicate a metabo-
lite aberration, the cause of which is still unknown.
The percentage distfibution of the unsaturated me^
tabolites was not uiiique in the fatal cases. Reversi-
ble valproic acid-induced side-effects (drowsiness,
J. Clin. Chem. Clin. Biochem. / Vol. 22, 1984 / No. 4
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CH2 = CHX
(E) 2.4- diene'
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Fig. 9. Preliminary metabolic scheme of valproic acid metabolism.
lethargy, vomiting, anorexia etc.) are known, and la-
boratory data (moderate increase in blood ammonia
and transaminases) indicate disturbed liver functions
in association with a changed valproic acid metabo-
lism. Preliminary results in such cases have demon-
strated that increased urinary diene/3 might be in-
dicative of a disturbed metabolic Situation, if its uri-
nary concentration is above the upper limit of 3%
(valproic acid plus all found metabolites = 100%)
(12). In addition, both the 4-ene and the 4.4'-diene
may be detected in traces.
It is very difficult to decide When vaiproic acid ther-
apy should be discontinued^ becäuse conventional
liver function tests do not seem to predict hepatotox-
icity. On rare occasions, valproic acid may initiate a
type of liver failure that almost always leads to the
death of the patient. The presence of side-effects as-
sociated with clinical signs of liver or pancreatic dys-
function, together with the appearance of the 4-ene,
and the 4.4'-diene, and increased excretion of the
diene/3 are an indication that valproic acid treat-
ment should be discontinued. One group of patients
has been identified, which is particularly at risk;
these are strongly retarded children with intractable
epilepsy on multiple antiepileptic drug therapy. At-
tention is imperative especially during the first 6
months after onset of valproic acid therapy.
References
1. Wilder, B. J. & Bruni, J. (1981) In: Seizure disorders: A
pharmacological approach to treatment, Chapter 7, Raven
Press New York.
2. Zirnmerman, H. J. & Ishak, K. G. (1982) Hepatology 2,
591-597.
3. yalprpate Symposium of the International Liga against Epi-
lepsy (September, 27, 1983 at Washington), to be published
in Epilepsia 1984.
4. Gram, L. (1983) In: Chronic toxicity of antiepileptic drugs
(Oxley, J., Janz,, D. & Meinardi, H., eds.). p. 69-77, Raven
Press New York.
5. Delgado-Escueta, A, V., Treiman, D. M. & Walsh, G. O.
(1983) N. Engl. J. Med. 308, 1576.
6. Kochen, W., Schneider, A. & Ritz, A. (1983) Eur. J. Pediatr.
141, 30-35.
7. Kochen, W. & Scheffner, D. (1980) In: Antiepileptic Ther-
apy: Advances in Drug Monitoring (Johannessen, S. L, Mor-
selli, P. L., Pippenger, C. E., Richens, A., Schmidt, D, & Mei-
nardi, H., eds.), pp. 111—120, Raven Press, 'New York.
8. Klemens, M. (1980) Diplomarbeit Universität Heidelberg.
J. Clin. Chem. Clin. Biochem. / Vol. 22, 1984 / No. 4
9. Barnett, R. N. (1947) J. Amer. Med. Assoc. 755, 28-30.
10. Conrad, M. & Bischoff, C. A. (1880) Liebigs Ann. Chemie
204, 138.
11. Schlosser, M. (1970) In: Topics in Stereochemistry (Eliel, E.
L. & Allinger, N. L., eds.) Vol. 5, p. l, Springer-Verlag Ber-
lin—Heidelberg—New York.
12. Kochen, W. & Sprunck, H. P. (1983) 57. Jahrestagung der
Dtsch. Ges. für NeUrologie und Jahrestagung der Dtsch. Sek-
tion der Intern. Liga gegen Epilepsie, Mannheim, October,
13th and 14th. To be published 1984 in: Epilepsie 1983,
(Hallen, O. & Meyer-Wahl, J. G., eds.), Georg Thieme Ver-
lag Stuttgart.
13. Holland, P. C, Senior, A. E. & Sherrat, H. S. A. (1973) Bio-
chem. J. 736, 173-184.
14. Glasgow, A. M. & Chase, P. (1975) Pediatr. Res. 9, 133-
138.
Prof. Dr. W. Kochen
Klinikum der Universität Heidelberg
Kinderklinik
Im Neuenheimer Feld 150
D-6900 Heidelberg

